Treatment of classical Hodgkin lymphoma in the era of brentuximab vedotin and immune checkpoint inhibitors

The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10–15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed. Salvage second-line therapy combined with high-dose therapy and autologous stem-cell tra...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hematology 2018-08, Vol.97 (8), p.1301-1315
Main Authors: Carella, A. M., Corradini, P., Mussetti, A., Ricardi, U., Vitolo, U., Viviani, S.
Format: Article
Language:English
Subjects:
Antineoplastic Agents, Immunological - administration & dosage
Antineoplastic Agents, Immunological - adverse effects
Antineoplastic Agents, Immunological - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Bleomycin - adverse effects
Bleomycin - therapeutic use
Combined Modality Therapy
Dacarbazine - adverse effects
Dacarbazine - therapeutic use
Doxorubicin - adverse effects
Doxorubicin - therapeutic use
Drug Resistance, Neoplasm
Hematology
Hodgkin Disease - diagnosis
Hodgkin Disease - drug therapy
Hodgkin Disease - immunology
Hodgkin Disease - mortality
Humans
Immunoconjugates - administration & dosage
Immunoconjugates - adverse effects
Immunoconjugates - therapeutic use
Immunomodulation - drug effects
Immunotherapy
Lymphoma
Medicine
Medicine & Public Health
Molecular Targeted Therapy
Monoclonal antibodies
Neoplasm Staging
Oncology
Positron-Emission Tomography
Retreatment
Review Article
Salvage Therapy
Targeted cancer therapy
Treatment Outcome
Vinblastine - adverse effects
Vinblastine - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The majority of Hodgkin lymphoma patients are now cured with conventional first-line therapy; however, 10–15% of early-stage disease and less than 30% of advanced-stage patients are refractory(rare) or relapsed. Salvage second-line therapy combined with high-dose therapy and autologous stem-cell transplantation can cure 40–50% of patients. Recently novel agents (Brentuximab Vedotin and Immune Checkpoint inhibitors) have demonstrated evidence of therapeutic activity and are potential bridge to an allogeneic stem-cell transplantation. The review is aimed to present not only salvage strategies; indeed, the paper contains paragraphs about therapy and new treatment options at diagnosis.
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-018-3366-x